Literature DB >> 25547502

Exploring the burden of inpatient readmissions after major cancer surgery.

Karyn B Stitzenberg1, YunKyung Chang2, Angela B Smith2, Matthew E Nielsen2.   

Abstract

PURPOSE: Travel distances to care have increased substantially with centralization of complex cancer procedures at high-volume centers. We hypothesize that longer travel distances are associated with higher rates of postoperative readmission and poorer outcomes.
METHODS: SEER-Medicare patients with bladder, lung, pancreas, or esophagus cancer who were diagnosed in 2001 to 2007 and underwent extirpative surgery were included. Readmission rates and survival were calculated using Kaplan-Meier functions. Multivariable negative binomial models were used to examine factors associated with readmission.
RESULTS: Four thousand nine hundred forty cystectomies, 1,573 esophagectomies, 20,362 lung resections, and 2,844 pancreatectomies were included. Thirty- and 90-day readmission rates ranged from 13% to 29% and 23% to 43%, respectively, based on tumor type. Predictors of readmission were discharge to somewhere other than home, longer length of stay, comorbidities, higher stage at diagnosis, and longer travel distance (P < .001 for each). Patients who lived farther from the index hospital also had increased emergency room visits and were more likely to be readmitted to a hospital other than the index hospital (P < .001). Of readmitted patients, 31.9% were readmitted more than once. Long-term survival was worse and costs of care higher for patients who were readmitted (P < .001 for all).
CONCLUSION: The burden of readmissions after major cancer surgery is high, resulting in substantially poorer patient outcomes and higher costs. Risk of readmission was most strongly associated with length of stay and discharge destination. Travel distance also has an impact on patterns of readmission. Interventions targeted at higher risk individuals could potentially decrease the population burden of readmissions after major cancer surgery.
© 2014 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2014        PMID: 25547502      PMCID: PMC4314594          DOI: 10.1200/JCO.2014.55.5938

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  27 in total

1.  Hospital volume, length of stay, and readmission rates in high-risk surgery.

Authors:  Philip P Goodney; Therese A Stukel; F Lee Lucas; Emily V A Finlayson; John D Birkmeyer
Journal:  Ann Surg       Date:  2003-08       Impact factor: 12.969

2.  Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series.

Authors:  C J Stimson; Sam S Chang; Daniel A Barocas; John E Humphrey; Sanjay G Patel; Peter E Clark; Joseph A Smith; Michael S Cookson
Journal:  J Urol       Date:  2010-08-17       Impact factor: 7.450

3.  Hospital readmission after pancreaticoduodenectomy.

Authors:  Dawn M Emick; Taylor S Riall; John L Cameron; Jordan M Winter; Keith D Lillemoe; Joann Coleman; Patricia K Sauter; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

4.  Readmissions following elective radical total gastrectomy for early gastric cancer: a case-controlled study.

Authors:  Yong-Deok Kim; Min-Chan Kim; Ki-Han Kim; Yoo-Min Kim; Ghap-Joong Jung
Journal:  Int J Surg       Date:  2014-01-07       Impact factor: 6.071

5.  Readmission after colectomy for cancer predicts one-year mortality.

Authors:  David Yu Greenblatt; Sharon M Weber; Erin S O'Connor; Noelle K LoConte; Jinn-Ing Liou; Maureen A Smith
Journal:  Ann Surg       Date:  2010-04       Impact factor: 12.969

6.  Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience.

Authors:  S Machele Donat; Ahmad Shabsigh; Caroline Savage; Angel M Cronin; Bernard H Bochner; Guido Dalbagni; Harry W Herr; Matthew I Milowsky
Journal:  Eur Urol       Date:  2008-07-14       Impact factor: 20.096

7.  Centralization of cancer surgery: implications for patient access to optimal care.

Authors:  Karyn B Stitzenberg; Elin R Sigurdson; Brian L Egleston; Russell B Starkey; Neal J Meropol
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

8.  Readmissions following pancreaticoduodenectomy for pancreas cancer: a population-based appraisal.

Authors:  Irina Yermilov; David Bentrem; Evan Sekeris; Sushma Jain; Melinda A Maggard; Clifford Y Ko; James S Tomlinson
Journal:  Ann Surg Oncol       Date:  2008-11-11       Impact factor: 5.344

9.  Validation of travel times to hospital estimated by GIS.

Authors:  Robin Haynes; Andrew P Jones; Violet Sauerzapf; Hongxin Zhao
Journal:  Int J Health Geogr       Date:  2006-09-19       Impact factor: 3.918

10.  Readmission after pancreatectomy for pancreatic cancer in Medicare patients.

Authors:  Deepthi M Reddy; Courtney M Townsend; Yong-Fang Kuo; Jean L Freeman; James S Goodwin; Taylor S Riall
Journal:  J Gastrointest Surg       Date:  2009-09-16       Impact factor: 3.452

View more
  48 in total

1.  Readmission Adversely Affects Survival in Surgical Rectal Cancer Patients.

Authors:  Sophia Y Chen; Miloslawa Stem; Susan L Gearhart; Bashar Safar; Sandy H Fang; Nilofer S Azad; Adrian G Murphy; Amol K Narang; Christopher L Wolfgang; Jonathan E Efron
Journal:  World J Surg       Date:  2019-10       Impact factor: 3.352

2.  Depressive Symptoms in Patients Scheduled for Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery: Prospective Associations With Morbidity and Mortality.

Authors:  Carissa A Low; Dana H Bovbjerg; Steven Ahrendt; Sara Alhelo; Haroon Choudry; Matthew Holtzman; Heather L Jones; James F Pingpank; Lekshmi Ramalingam; Herbert J Zeh; Amer H Zureikat; David L Bartlett
Journal:  J Clin Oncol       Date:  2016-02-22       Impact factor: 44.544

3.  The clinical and economic burden of perioperative complications of radical cystectomy.

Authors:  Christine W Liaw; Jared S Winoker; Peter Wiklund; John Sfakianos; Matthew D Galsky; Reza Mehrazin
Journal:  Transl Androl Urol       Date:  2019-07

4.  [Economic aspects of oncological esophageal surgery : Centralization is essential].

Authors:  N von Dercks; I Gockel; M Mehdorn; D Lorenz
Journal:  Chirurg       Date:  2017-01       Impact factor: 0.955

5.  Predictors of Unplanned Hospitalizations in Patients With Nonmetastatic Lung Cancer During Chemotherapy.

Authors:  Kristen L Fessele; Matthew J Hayat; Robert L Atkins
Journal:  Oncol Nurs Forum       Date:  2017-09-01       Impact factor: 2.172

6.  Fragmentation of Care after Surgical Discharge: Non-Index Readmission after Major Cancer Surgery.

Authors:  Chaoyi Zheng; Elizabeth B Habermann; Nawar M Shara; Russell C Langan; Young Hong; Lynt B Johnson; Waddah B Al-Refaie
Journal:  J Am Coll Surg       Date:  2016-02-05       Impact factor: 6.113

7.  Fitbit step counts during inpatient recovery from cancer surgery as a predictor of readmission.

Authors:  Carissa A Low; Dana H Bovbjerg; Steven Ahrendt; M Haroon Choudry; Matthew Holtzman; Heather L Jones; James F Pingpank; Lekshmi Ramalingam; Herbert J Zeh; Amer H Zureikat; David L Bartlett
Journal:  Ann Behav Med       Date:  2018-01-05

8.  Longer average blood storage duration is associated with increased risk of infection and overall morbidity following radical cystectomy.

Authors:  Meera R Chappidi; Heather J Chalfin; Daniel J Johnson; Max Kates; Nikolai A Sopko; Michael H Johnson; Jen-Jane Liu; Steven M Frank; Trinity J Bivalacqua
Journal:  Urol Oncol       Date:  2016-10-19       Impact factor: 3.498

Review 9.  Bending the Cost Curve in Childhood Cancer.

Authors:  Heidi Russell; M Brooke Bernhardt
Journal:  Curr Hematol Malig Rep       Date:  2016-08       Impact factor: 3.952

10.  Quantifying Nonindex Hospital Readmissions and Care Fragmentation after Major Urological Oncology Surgeries in a Nationally Representative Sample.

Authors:  Meera R Chappidi; Max Kates; C J Stimson; Trinity J Bivalacqua; Phillip M Pierorazio
Journal:  J Urol       Date:  2016-07-25       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.